Business Wire

MA-EXCEL-DRYER

30.6.2020 22:17:10 CEST | Business Wire | Press release

Share
Leading Health Organizations Recommend the Use of Hand Dryers

The topic of hygiene has come to the forefront in mainstream media as reopening plans are introduced around the globe. While leading health organizations like the World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC), recommend the use of hand dryers, misinformation about them remains online, and continues to be quoted and perpetuated. Leaders from Excel Dryer , manufacturer of XLERATOR® Hand Dryers, wish to deliver a message to educate the professionals, consultants and government officials who are creating reopening guidelines, and the general public, especially in times of COVID-19: Excel hand dryers are a safe, hygienic touchless solution and an effective way to achieve completely dry hands, a critical part of proper hand hygiene , the top defense against the spread of germs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630006010/en/

Kelly Reynolds, Ph.D., Professor and Department Chair at the Mel & Enid Zuckerman College of Public Health at the University of Arizona, offered an explanation as to the root of these misconceptions, stating that, “Consumers may only read [sensationalized] headlines which can influence public opinion toward biased or erroneous conclusions, [but] the fact is, the breadth of data available does not favor one hand drying method as being more hygienic or safer.”

Excel hand dryers provide a touchless hand drying solution to help prevent potential cross-contamination between restroom surfaces and wet hands. All dryers in Excel’s line are hygienic, but dryers with HEPA have been proven to add another level of protection. Viral efficiency testing conducted by the preeminent independent air media and filter testing company, LMS Technologies in April of 2020 found that XLERATOR® , XLERATOReco ® and XLERATORsync® Hand Dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream.

William Gagnon, vice president of marketing and sales at Excel Dryer, wishes to correct misinformation and biases about hand dryers. “Hand dryers are hygienic and have been used to properly dry hands for decades. In addition to top health organizations recommending their use, hand dryers also provide significant benefits over paper that are undisputable. For example, our recent test results prove XLERATOR hand dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream, something paper will never be able to do.”

Conversely, paper towels may not be as hygienic as the public believes. One independent study showed 17 species of bacteria on unused, recycled paper towels , including Bacillus, which can cause food poisoning. After their use, damp paper towels are a breeding ground for viruses and bacteria in and around trash receptacles and can be used to clog toilets and sinks creating a very unhygienic restroom environment. If the paper towels are out of stock, visitors cannot dry their hands at all, and wet hands have been shown to be 1,000 times more likely to transfer germs than dry hands .

Gagnon concluded, “I encourage members of the public and those individuals charged with the creation of guidelines, reopening plans or facilities operations, to dive deeper into news articles and hygiene studies rather than simply believing sensationalized, click-bait headlines born from biased results. Hand dryers are safe and hygienic. They dry hands completely, and are a top defense against the spread of germs.”

About Excel Dryer, Inc.

Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/xlerator

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye